Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications.
Frontiers in pharmacology January 1, 2024 Senbing Zhang, Yanzhu Pu, Jianning Liu et al. 12 citations
(R)-ketamine shows promise for treatment-resistant depression with fewer psychomimetic and dissociative side effects than (R,S)- or (S)-ketamine, but a recent small randomized controlled trial found its antidepressant efficacy did not surpass placebo in adults. The compound may also have applications in cognitive disorders, stroke, Parkinson's disease, multiple sclerosis, osteoporosis, substance use disorders, inflammatory diseases, COVID-19, and organophosphate poisoning. This review covers (R)-ketamine's mechanisms and antidepressant research, highlighting its potential and need for further verification.